A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis
A Randomized, Double Blind, Placebo-controlled, Dose Response, Phase II, Multicentre Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Oral CR6086 Administered at the Doses of 30, 90 or 180 mg Bid for 12 Weeks in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis
Sponsor: Rottapharm Biotech
A PHASE2 clinical study on Rheumatoid Arthritis, DMARD-naive and Early Disease Patients, this trial is completed. The trial is conducted by Rottapharm Biotech and has accumulated 8 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jan 2021 — Nov 2021 [monthly]
Unknown Status PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2020 [monthly]
Recruiting PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2017 — Jan 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Rottapharm Biotech
For direct contact, visit the study record on ClinicalTrials.gov .